article thumbnail

7 Strategies To Solve Your Business Problems Faster

Startup Professionals Musings

Way back in 2004, he cared enough about an associate's injury to spend time investigating, and used the exercise to isolate a root cause without blaming anyone. Make sure that you implement a metric with each solution, to prevent the issue from recurring, and check for side effects and follow-on side effects.

Dividend 382
article thumbnail

State of VC 2.0

View from Seed

Warning – this assumes some basic knowledge of VC performance metrics. One thing that jumps out quickly is that TVPI between 2004-2010 (avg 2.6x) has underperformed 2011-2017 (avg 3.0x). For context, seed-stage pre-money valuations are up 24% from H1 2020 to H1 2021. Ok, let’s jump in. State of VC: are we in a bubble?

Valuation 319
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

State of VC 2.0

View from Seed

Warning – this assumes some basic knowledge of VC performance metrics. One thing that jumps out quickly is that TVPI between 2004-2010 (avg 2.6x) has underperformed 2011-2017 (avg 3.0x). For context, seed-stage pre-money valuations are up 24% from H1 2020 to H1 2021. Ok, let’s jump in. State of VC: are we in a bubble?

Valuation 295
article thumbnail

State of VC 2.0

View from Seed

Warning – this assumes some basic knowledge of VC performance metrics. One thing that jumps out quickly is that TVPI between 2004-2010 (avg 2.6x) has underperformed 2011-2017 (avg 3.0x). For context, seed-stage pre-money valuations are up 24% from H1 2020 to H1 2021. Ok, let’s jump in. State of VC: are we in a bubble?

Valuation 156
article thumbnail

When Entry Multiples Don’t Matter

Ben's Blog

A multiple is a company value divided by a metric. When Salesforce went public in 2004 as a new kind of CRM provider, its S-1 indicated the CRM applications market was $7B. The management teams of both companies may want to be valued at 15x 2020 revenue — in other words, both companies would be worth $300 million.

article thumbnail

Out of the Crisis #5, ANA Therapeutics: a possible COVID-19 treatment and prophylactic

Startup Lessons Learned

And so, when we said that jokingly, Nadja diligently started going through the literature research, and in five minutes pulled up a paper saying, "Well, here's a paper that shows that during the SARS outbreak in 2004, niclosamide was actually a very potent inhibitor of viral replication." But I think that, again, this is hindsight being 2020.